tetano
Editor, Senior Moderator
Transpl Int
. 2022 Mar 31;35:10109.
doi: 10.3389/ti.2022.10109. eCollection 2022.
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients
Friederike Bachmann[SUP] 1 [/SUP], Klemens Budde[SUP] 1 [/SUP], Norbert Suttorp[SUP] 2 [/SUP], Tilman Lingscheid[SUP] 2 [/SUP], Miriam Songa Stegemann[SUP] 2 [/SUP], Bilgin Osmanodja[SUP] 1 [/SUP], Eva Schrezenmeier[SUP] 1 3 [/SUP], Wiebke Duettmann[SUP] 1 [/SUP], Ulrike Weber[SUP] 1 [/SUP], Marcel Naik[SUP] 1 [/SUP], Lukas Johannes Lehner[SUP] 1 [/SUP], Andreas Kahl[SUP] 1 [/SUP], Michael Duerr[SUP] 1 [/SUP], Kai-Uwe Eckardt[SUP] 1 [/SUP], Johannes Waiser[SUP] 1 [/SUP], Mira Choi[SUP] 1 [/SUP], Fabian Halleck[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal antibodies (mAb) targeting the viral spike protein: bamlanivimab and casivirimab and imdevimab. As per the EUA, all SARS-CoV-2 positive organ transplant recipients can receive mAb treatment. Patients and methods: We queried our center's transplant registry to identify SARS-CoV-2 infected recipients treated with single doses of either Bamlanivimab or casivirimab/imdevimab up to May 31, 2021. We analyzed clinical outcomes, renal function and virus-specific antibodies. The co-primary endpoints were hospitalization due to COVID-19 and SARS-CoV-2 RT-PCR negativity. Results: Thirteen patients at a median interval of 55 (IQR, 26-110) months from transplant were treated: 8 with bamlanivimab and 5 with casivirimab/imdevimab. In all, 4/13 (31%) patients were hospitalized at some time, while 11/13 (85%) achieved PCR negativity. 2/4 hospitalized patients received mAb as rescue treatment. Overall mortality was 23%, with one death attributable to transplant-associated lymphoma. All six patients infected with the B 1.1.7 variant were alive at last contact. Conclusion: mAb treatment appears effective when administered early to SARS-CoV-2-infected transplant recipients.
Keywords: SARS-CoV-2; bamlanivimab; immunosuppression; kidney transplantation; monoclonal antibodies.
. 2022 Mar 31;35:10109.
doi: 10.3389/ti.2022.10109. eCollection 2022.
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients
Friederike Bachmann[SUP] 1 [/SUP], Klemens Budde[SUP] 1 [/SUP], Norbert Suttorp[SUP] 2 [/SUP], Tilman Lingscheid[SUP] 2 [/SUP], Miriam Songa Stegemann[SUP] 2 [/SUP], Bilgin Osmanodja[SUP] 1 [/SUP], Eva Schrezenmeier[SUP] 1 3 [/SUP], Wiebke Duettmann[SUP] 1 [/SUP], Ulrike Weber[SUP] 1 [/SUP], Marcel Naik[SUP] 1 [/SUP], Lukas Johannes Lehner[SUP] 1 [/SUP], Andreas Kahl[SUP] 1 [/SUP], Michael Duerr[SUP] 1 [/SUP], Kai-Uwe Eckardt[SUP] 1 [/SUP], Johannes Waiser[SUP] 1 [/SUP], Mira Choi[SUP] 1 [/SUP], Fabian Halleck[SUP] 1 [/SUP]
Affiliations
- PMID: 35431640
- PMCID: PMC9008834
- DOI: 10.3389/ti.2022.10109
Abstract
Background: Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal antibodies (mAb) targeting the viral spike protein: bamlanivimab and casivirimab and imdevimab. As per the EUA, all SARS-CoV-2 positive organ transplant recipients can receive mAb treatment. Patients and methods: We queried our center's transplant registry to identify SARS-CoV-2 infected recipients treated with single doses of either Bamlanivimab or casivirimab/imdevimab up to May 31, 2021. We analyzed clinical outcomes, renal function and virus-specific antibodies. The co-primary endpoints were hospitalization due to COVID-19 and SARS-CoV-2 RT-PCR negativity. Results: Thirteen patients at a median interval of 55 (IQR, 26-110) months from transplant were treated: 8 with bamlanivimab and 5 with casivirimab/imdevimab. In all, 4/13 (31%) patients were hospitalized at some time, while 11/13 (85%) achieved PCR negativity. 2/4 hospitalized patients received mAb as rescue treatment. Overall mortality was 23%, with one death attributable to transplant-associated lymphoma. All six patients infected with the B 1.1.7 variant were alive at last contact. Conclusion: mAb treatment appears effective when administered early to SARS-CoV-2-infected transplant recipients.
Keywords: SARS-CoV-2; bamlanivimab; immunosuppression; kidney transplantation; monoclonal antibodies.